Namilumab
Namilumab
Jump to navigation
Jump to search
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CSF2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number |
|
| ChemSpider |
|
| UNII |
|
 N Y (what is this?) (verify) | |
Namilumab (alternative identifier MT203) is a human monoclonal antibody (class IgG1 kappa) that targets granulocyte macrophage-colon stimulating factor (GM-CSF)/colony stimulating factor 2 (CSF2) and is currently being researched for application in rheumatoid arthritis (RA) and psoriatic arthritis.[1][2][3] Clinical trials investigating the therapeutic utility of Namilumab have include phase I and phase II clinical trials to establish the safety, tolerability and preliminary therapeutic utility of the antibody in plaque psoriasis[4] and rheumatoid arthritis.[5][6]
Namilumab was produced by Micromet Inc and is under development by Takeda Pharmaceuticals International.[3][7]
References[edit]
^ World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104" (PDF). WHO Drug Information. 24 (4)..mw-parser-output cite.citationfont-style:inherit.mw-parser-output qquotes:"""""""'""'".mw-parser-output code.cs1-codecolor:inherit;background:inherit;border:inherit;padding:inherit.mw-parser-output .cs1-lock-free abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-limited a,.mw-parser-output .cs1-lock-registration abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-lock-subscription abackground:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registrationcolor:#555.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration spanborder-bottom:1px dotted;cursor:help.mw-parser-output .cs1-hidden-errordisplay:none;font-size:100%.mw-parser-output .cs1-visible-errorfont-size:100%.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-formatfont-size:95%.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-leftpadding-left:0.2em.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-rightpadding-right:0.2em
^ "Meeting Abstract: Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA)".
^ ab "Namilumab - AdisInsight". adisinsight.springer.com. Retrieved 2017-03-24.
^ "Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24.
^ "A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate - AdisInsight". adisinsight.springer.com. Retrieved 2017-03-24.
^ "Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA) - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2017-03-24.
^ "Takeda clinical trials summary:Namilumab".
 | This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibodies
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
(window.RLQ=window.RLQ||).push(function()mw.config.set("wgPageParseReport":"limitreport":"cputime":"0.696","walltime":"3.317","ppvisitednodes":"value":4188,"limit":1000000,"ppgeneratednodes":"value":0,"limit":1500000,"postexpandincludesize":"value":131275,"limit":2097152,"templateargumentsize":"value":1887,"limit":2097152,"expansiondepth":"value":16,"limit":40,"expensivefunctioncount":"value":1,"limit":500,"unstrip-depth":"value":1,"limit":20,"unstrip-size":"value":19089,"limit":5000000,"entityaccesscount":"value":1,"limit":400,"timingprofile":["100.00% 3104.033 1 -total"," 80.06% 2484.938 1 Template:Drugbox"," 44.81% 1390.958 1 Template:Infobox"," 12.76% 396.179 16 Template:Unbulleted_list"," 11.12% 345.031 1 Template:Infobox_drug/mab_source"," 7.15% 221.978 1 Template:Infobox_drug/chemical_formula"," 6.78% 210.472 1 Template:Button"," 6.68% 207.225 2 Template:Asbox"," 6.65% 206.406 1 Template:Monoclonal-antibody-stub"," 6.56% 203.632 1 Template:Linear-gradient"],"scribunto":"limitreport-timeusage":"value":"0.263","limit":"10.000","limitreport-memusage":"value":4244369,"limit":52428800,"cachereport":"origin":"mw1262","timestamp":"20181010143309","ttl":1900800,"transientcontent":false);mw.config.set("wgBackendResponseTime":3655,"wgHostname":"mw1262"););
Clash Royale CLAN TAG